Bio-Gene Technology Limited, a biotechnology company, engages in developing insecticides/pesticides for animal health, crop protection, public health, and consumer applications in Australia.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.14|
|52 Week High||AU$0.12|
|52 Week Low||AU$0.21|
|1 Month Change||0%|
|3 Month Change||-9.68%|
|1 Year Change||-20.00%|
|3 Year Change||-17.65%|
|5 Year Change||n/a|
|Change since IPO||-30.00%|
Recent News & Updates
Here's Why We're Not At All Concerned With Bio-Gene Technology's (ASX:BGT) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Bio-Gene Technology Limited (ASX:BGT) Is Expected To Breakeven In The Near Future
Bio-Gene Technology Limited ( ASX:BGT ) is possibly approaching a major achievement in its business, so we would like...
|BGT||AU Chemicals||AU Market|
Return vs Industry: BGT underperformed the Australian Chemicals industry which returned 11.3% over the past year.
Return vs Market: BGT underperformed the Australian Market which returned 20.2% over the past year.
Stable Share Price: BGT is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: BGT's weekly volatility (10%) has been stable over the past year.
About the Company
Bio-Gene Technology Limited, a biotechnology company, engages in developing insecticides/pesticides for animal health, crop protection, public health, and consumer applications in Australia. It is involved in developing Flavocide, a beta-triketone insecticide product; and Qcide, a natural oil extracted from the leaves of rare eucalyptus trees. The company has a research collaboration agreement with James Cook University for the development of a tissue culture system to support the expansion of tree plantations and scale-up of future Qcide oil production.
Bio-Gene Technology Fundamentals Summary
|BGT fundamental statistics|
Is BGT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BGT income statement (TTM)|
|Cost of Revenue||AU$118.98k|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.016|
|Net Profit Margin||-3,827.29%|
How did BGT perform over the long term?See historical performance and comparison
Is Bio-Gene Technology undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate BGT's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate BGT's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: BGT is unprofitable, so we can't compare its PE Ratio to the Australian Chemicals industry average.
PE vs Market: BGT is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BGT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BGT is overvalued based on its PB Ratio (5.1x) compared to the AU Chemicals industry average (4x).
How is Bio-Gene Technology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Materials industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Bio-Gene Technology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Bio-Gene Technology performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BGT is currently unprofitable.
Growing Profit Margin: BGT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BGT is unprofitable, and losses have increased over the past 5 years at a rate of 9% per year.
Accelerating Growth: Unable to compare BGT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BGT is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-61.8%).
Return on Equity
High ROE: BGT has a negative Return on Equity (-56.43%), as it is currently unprofitable.
How is Bio-Gene Technology's financial position?
Financial Position Analysis
Short Term Liabilities: BGT's short term assets (A$4.7M) exceed its short term liabilities (A$592.7K).
Long Term Liabilities: BGT's short term assets (A$4.7M) exceed its long term liabilities (A$161.9K).
Debt to Equity History and Analysis
Debt Level: BGT is debt free.
Reducing Debt: BGT has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BGT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: BGT has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 9.2% each year.
What is Bio-Gene Technology current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BGT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BGT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BGT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BGT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BGT's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Richard Jagger, BSC (HONS), M.INTL.BUS, GAICD has been the Managing Director and Chief Executive Officer at cLtd since January 1,2018 and served as its Head of Commercial Development since May 26, 2017...
CEO Compensation Analysis
Compensation vs Market: Richard's total compensation ($USD376.31K) is about average for companies of similar size in the Australian market ($USD302.72K).
Compensation vs Earnings: Richard's compensation has increased whilst the company is unprofitable.
Experienced Management: BGT's management team is considered experienced (3.8 years average tenure).
Experienced Board: BGT's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Bio-Gene Technology Limited's employee growth, exchange listings and data sources
- Name: Bio-Gene Technology Limited
- Ticker: BGT
- Exchange: ASX
- Founded: 1995
- Industry: Fertilizers and Agricultural Chemicals
- Sector: Materials
- Market Cap: AU$21.509m
- Shares outstanding: 153.63m
- Website: https://www.bio-gene.com.au
- Bio-Gene Technology Limited
- 456 Lonsdale Street
- Level 11
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/17 07:03|
|End of Day Share Price||2021/10/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.